Related Experiment Video
Updated: Jun 25, 2026
05:50
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
Published on: September 26, 2025
3D pharmacophore models for thromboxane A(2) receptor antagonists
Jing Wei1, Yixi Liu, Songqing Wang
1Tianjin University, Nankai District, PR China.
Journal of Molecular Modeling
|March 6, 2009
Summary
This study uses computational drug design to build pharmacophore models for Thromboxane A(2) receptor antagonists (TXRAs). These models reveal key structure-activity relationships, aiding in the development of new cardiovascular disease treatments.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Pharmacology
Background:
- Thromboxane A(2) (TXA(2)) is linked to thrombosis and cardiovascular diseases.
- TXA(2) receptor antagonists (TXRAs) can inhibit TXA(2) action.
- Existing studies on TXA(2) receptor-ligand interactions lack consensus.
Purpose of the Study:
- To investigate the structure-activity relationship (SAR) of TXRAs using computational drug design.
- To develop predictive pharmacophore models for TXRAs.
Main Methods:
- Ligand-based computational drug design was employed.
- Three-dimensional pharmacophore models were generated using CATALYST software (HypoGenRefine and HipHop modules).
- Model development was based on a dataset of 25 TXRAs.
Main Results:
- An optimal HypoGenRefine model identified two hydrophobic groups, an aromatic ring, a hydrogen-bond acceptor, and four excluded volumes.
- An optimal HipHop model revealed two hydrophobic groups and two hydrogen-bond acceptors.
- The models effectively describe TXRA SAR.
Conclusions:
- The developed pharmacophore models provide insights into TXRA structure-activity relationships.
- These models can predict the activity of novel TXRA compounds.
- The findings facilitate the rational design of new TXRA-based therapeutics for cardiovascular conditions.
Related Concept Videos
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:20Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...